Cargando…
Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective
The aim of this study was to assess the prevalence of germline variants in cancer-predisposing genes by either targeted (BRCA1/2) or multigene NGS panel in a high-risk Hereditary Breast and Ovarian Cancer (HBOC) cohort. Samples from 824 Caucasian probands were retrospectively collected and the impac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130174/ https://www.ncbi.nlm.nih.gov/pubmed/35451682 http://dx.doi.org/10.1007/s00438-022-01891-5 |
_version_ | 1784712931008577536 |
---|---|
author | Molina-Zayas, María Garrido-Navas, Carmen García-Puche, Jose Luis Barwell, Julian Pedrinaci, Susana Atienza, Margarita Martínez García-Linares, Susana de Haro-Muñoz, Tomás Lorente, Jose Antonio Serrano, M. Jose Poyatos-Andújar, Antonio |
author_facet | Molina-Zayas, María Garrido-Navas, Carmen García-Puche, Jose Luis Barwell, Julian Pedrinaci, Susana Atienza, Margarita Martínez García-Linares, Susana de Haro-Muñoz, Tomás Lorente, Jose Antonio Serrano, M. Jose Poyatos-Andújar, Antonio |
author_sort | Molina-Zayas, María |
collection | PubMed |
description | The aim of this study was to assess the prevalence of germline variants in cancer-predisposing genes by either targeted (BRCA1/2) or multigene NGS panel in a high-risk Hereditary Breast and Ovarian Cancer (HBOC) cohort. Samples from 824 Caucasian probands were retrospectively collected and the impact of genetic diagnosis and genetic variants epidemiology in this cohort was evaluated. Performance of risk-reducing prophylactic measures, such as prophylactic mastectomy and/or prophylactic oophorectomy, was assessed through clinical follow-up of patients with a positive genetic result. Pathogenic variants predisposing to HBOC were identified in 11.9% (98/824) individuals at BRCA2 (47/98), BRCA1 (24/98), PALB2 (8/51), ATM (7/51), CHEK2 (6/51) MSH6, (2/51), RAD51C (2/51) and TP53 (2/386). Of them, 11 novel pathogenic variants and 12 VUS were identified, characterized, and submitted to ClinVar. Regarding clinical impact, the risk of developing basal or Her2 breast cancer was increased 15.7 times or 37.5 times for BRCA1 and MSH6 pathogenic variants respectively. On the contrary, the risk of developing basal or luminal A breast cancer was reduced to 81% or 77% for BRCA2 and BRCA1 pathogenic variants, respectively. Finally, 53.2% of individuals testing positive for class IV/V variants underwent prophylactic surgery (mastectomy, oophorectomy or both) being significantly younger at the cancer diagnosis than those undertaking prophylactic measures (p = 0.008). Of them, 8 carried a pathogenic/likely pathogenic variant in other genes different from BRCA1 and BRCA2, and the remaining (46.7%) decided to continue with clinical follow-up. No differences in pathogenicity or risk of developing cancer were found for BRCA1/2 between targeted and multigene sequencing strategies; however, NGS was able to resolve a greater proportion of high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00438-022-01891-5. |
format | Online Article Text |
id | pubmed-9130174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-91301742022-05-26 Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective Molina-Zayas, María Garrido-Navas, Carmen García-Puche, Jose Luis Barwell, Julian Pedrinaci, Susana Atienza, Margarita Martínez García-Linares, Susana de Haro-Muñoz, Tomás Lorente, Jose Antonio Serrano, M. Jose Poyatos-Andújar, Antonio Mol Genet Genomics Original Article The aim of this study was to assess the prevalence of germline variants in cancer-predisposing genes by either targeted (BRCA1/2) or multigene NGS panel in a high-risk Hereditary Breast and Ovarian Cancer (HBOC) cohort. Samples from 824 Caucasian probands were retrospectively collected and the impact of genetic diagnosis and genetic variants epidemiology in this cohort was evaluated. Performance of risk-reducing prophylactic measures, such as prophylactic mastectomy and/or prophylactic oophorectomy, was assessed through clinical follow-up of patients with a positive genetic result. Pathogenic variants predisposing to HBOC were identified in 11.9% (98/824) individuals at BRCA2 (47/98), BRCA1 (24/98), PALB2 (8/51), ATM (7/51), CHEK2 (6/51) MSH6, (2/51), RAD51C (2/51) and TP53 (2/386). Of them, 11 novel pathogenic variants and 12 VUS were identified, characterized, and submitted to ClinVar. Regarding clinical impact, the risk of developing basal or Her2 breast cancer was increased 15.7 times or 37.5 times for BRCA1 and MSH6 pathogenic variants respectively. On the contrary, the risk of developing basal or luminal A breast cancer was reduced to 81% or 77% for BRCA2 and BRCA1 pathogenic variants, respectively. Finally, 53.2% of individuals testing positive for class IV/V variants underwent prophylactic surgery (mastectomy, oophorectomy or both) being significantly younger at the cancer diagnosis than those undertaking prophylactic measures (p = 0.008). Of them, 8 carried a pathogenic/likely pathogenic variant in other genes different from BRCA1 and BRCA2, and the remaining (46.7%) decided to continue with clinical follow-up. No differences in pathogenicity or risk of developing cancer were found for BRCA1/2 between targeted and multigene sequencing strategies; however, NGS was able to resolve a greater proportion of high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00438-022-01891-5. Springer Berlin Heidelberg 2022-04-22 2022 /pmc/articles/PMC9130174/ /pubmed/35451682 http://dx.doi.org/10.1007/s00438-022-01891-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Molina-Zayas, María Garrido-Navas, Carmen García-Puche, Jose Luis Barwell, Julian Pedrinaci, Susana Atienza, Margarita Martínez García-Linares, Susana de Haro-Muñoz, Tomás Lorente, Jose Antonio Serrano, M. Jose Poyatos-Andújar, Antonio Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title | Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title_full | Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title_fullStr | Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title_full_unstemmed | Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title_short | Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective |
title_sort | identification of hereditary breast and ovarian cancer germline variants in granada (spain): ngs perspective |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130174/ https://www.ncbi.nlm.nih.gov/pubmed/35451682 http://dx.doi.org/10.1007/s00438-022-01891-5 |
work_keys_str_mv | AT molinazayasmaria identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT garridonavascarmen identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT garciapuchejoseluis identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT barwelljulian identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT pedrinacisusana identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT atienzamargaritamartinez identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT garcialinaressusana identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT deharomunoztomas identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT lorentejoseantonio identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT serranomjose identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective AT poyatosandujarantonio identificationofhereditarybreastandovariancancergermlinevariantsingranadaspainngsperspective |